What is Radyalis?
Radyalis operates at the intersection of medical physics and software engineering, specializing in advanced cancer radiation therapy solutions. The company is best known for developing a high-speed, high-accuracy Monte Carlo dose calculator that supports photon, electron, and proton therapies. By optimizing the clinical application of Monte Carlo methods, Radyalis enables practitioners to execute adaptive radiation therapy with unprecedented precision. This technological edge allows for more confident treatment planning and improved clinical workflows, effectively bridging the gap between complex physics simulations and practical, real-time patient care. As the industry shifts toward more personalized medicine, the company's ability to integrate emerging ion therapies positions it as a critical infrastructure provider for modern oncology centers.
How much funding has Radyalis raised?
Radyalis has raised a total of $52K across 1 funding round:
Debt
$52K
Debt (2021): $52K with participation from PPP
Key Investors in Radyalis
PPP
Public-Private Partnership
What's next for Radyalis?
With the recent infusion of capital, Radyalis is expected to scale its operational footprint and deepen its research and development efforts in particle therapy. The strategic focus will likely center on expanding the software's compatibility with diverse treatment modalities and enhancing its integration capabilities within existing hospital information systems. As the company matures through its current growth phase, the emphasis will remain on maintaining its competitive advantage in computational speed and accuracy, which are essential for the next generation of adaptive radiotherapy. Investors will be monitoring the firm's ability to capture market share in the global radiation oncology market, particularly as clinical demand for more precise, personalized treatment plans continues to rise.
See full Radyalis company page
